Fisetin
Fisetin (3,3,4,5,7-pentahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, persimmons, onions, and cucumbers that has emerged as one of the most potent senolytics identified among plant polyphenols. Its primary mechanism of action is selective induction of apoptosis in senescent cells by disrupting the prosurvival Bcl-2 family signaling network that underlies the senescent cell anti-apoptosis program (SCAP), while sparing normal, non-senescent cells. Beyond senolysis, fisetin activates SIRT1 deacetylase activity, induces autophagy via PI3K/Akt/mTOR suppression and ULK1 activation, reduces the senescence-associated secretory phenotype (SASP) inflammatory burden, and exerts neuroprotective effects through multiple anti-inflammatory and neurotrophic mechanisms. In the landmark Mayo Clinic/University of Minnesota fisetin trial (Yousefzadeh et al., 2018), fisetin eliminated over 50% of circulating senescent T cells in aged mice and reduced frailty index scores significantly, placing it at the forefront of translational senolytic research.
Key Takeaways
- •Fisetin is among the most potent natural senolytics identified to date, demonstrating senolytic activity in vitro at concentrations achievable with supplementation and in vivo in multiple aged animal models. The foundational 2018 study by Yousefzadeh et al. (EBioMedicine, n=mice) showed fisetin reduced senescent cell burden by more than 50% in circulating blood, adipose tissue, and liver of aged mice, reduced the SASP inflammatory mediators TNF-alpha, IL-6, and MCP-1, and significantly improved physical function and frailty composite scores compared to vehicle-treated aged controls.
- •The molecular target of fisetin senolytic activity is the Bcl-2 family prosurvival network. Senescent cells upregulate Bcl-2, Bcl-xL (BCL2L1), and Bcl-W to resist intrinsic apoptosis, creating the senescent cell anti-apoptosis program (SCAP). Fisetin inhibits Bcl-2 and Bcl-xL, tipping the balance toward pro-apoptotic proteins BAX and BAK, which oligomerize on the mitochondrial outer membrane, releasing cytochrome c and activating caspase-9 and caspase-3. This mechanism is selectively toxic to senescent cells because normal cells rely less heavily on these prosurvival factors.
- •Fisetin reduces p16INK4a (CDKN2A) expression in multiple tissue types in vivo, a finding with major implications for aging biology. p16INK4a is the canonical biomarker of cellular senescence and a direct cause of proliferative arrest in stem cell compartments. By reducing the senescent cell burden that drives p16 accumulation, fisetin improves tissue regenerative capacity. A 2021 preclinical study found that fisetin treatment in aged mice reduced p16 mRNA expression in multiple tissues by 40-60%, correlating with improvements in physical function.
- •The autophagy-inducing properties of fisetin complement its senolytic effects through a distinct mechanism. Fisetin inhibits the PI3K/Akt/mTOR signaling axis, a suppressor of autophagy initiation. Reduced mTORC1 activity relieves inhibition of ULK1 (the autophagy-initiating kinase), promoting autophagosome formation and the clearance of damaged organelles and protein aggregates. This mTOR-independent longevity pathway activation positions fisetin as both a senolytic (eliminating senescent cells) and a senomorphic (improving the function of remaining cells through autophagy enhancement).
- •SIRT1 activation by fisetin provides a third independent longevity mechanism. SIRT1 is a NAD+-dependent deacetylase that regulates metabolic adaptation, DNA repair, inflammation, and cellular stress responses. Fisetin upregulates SIRT1 expression and activity, promoting SIRT1-mediated deacetylation of downstream targets including PGC-1alpha (mitochondrial biogenesis), FOXO3 (stress resistance genes), and NF-kappaB p65 (anti-inflammatory). A 2018 study in Redox Biology found that fisetin-induced SIRT1 activation in neuronal cells reduced oxidative stress markers by 45% and increased mitochondrial membrane potential, providing mechanistic support for its neuroprotective effects.
- •Human translation of fisetin senolytic activity is underway through the AFFIRM-LITE trial (NCT04232085), a Phase 2 RCT at Mayo Clinic testing intermittent high-dose fisetin (20 mg/kg/day for 3 consecutive days) in older adults with metabolic syndrome. Interim results have been encouraging, showing reductions in senescence biomarkers including p21, p16, and SASP markers in peripheral blood mononuclear cells. The intermittent dosing protocol (3 consecutive days per month or per 2 months) is based on pharmacokinetic modeling suggesting that senescent cells require days of fisetin exposure to undergo apoptosis, after which fisetin can be cleared before the next cycle.
- •Fisetin bioavailability is substantially limited by rapid phase II metabolism: fisetin undergoes glucuronidation and sulfation in the intestinal wall and liver, producing water-soluble conjugates that are rapidly excreted. Peak plasma concentrations after a 100 mg oral dose reach approximately 200-400 nM, which is below the 5-10 micromol/L concentrations needed for senolytic activity in some cell culture systems, though in vivo tissue concentrations may be higher. Liposomal, nanoparticle, and phospholipid complex formulations significantly improve bioavailability and are the recommended formulations for senolytic protocols.
Basic Information
- Name
- Fisetin
- Also Known As
- 3,3,4,5,7-pentahydroxyflavone3,7,3,4-tetrahydroxyflavonefisetin flavonoidfustel
- Category
- Flavonoid / Senolytic / SIRT1 activator
- Bioavailability
- Fisetin has poor oral bioavailability due to rapid phase II metabolism (glucuronidation and sulfation) in intestinal enterocytes and hepatocytes, producing hydrophilic conjugates that are rapidly excreted in urine and bile. Peak plasma concentrations after a 100 mg oral dose of standard fisetin reach approximately 200-400 nM free fisetin, well below the 5-20 micromol/L concentrations effective in cell culture senolysis assays. Lipid-based delivery systems including liposomal encapsulation, PLGA nanoparticles, and phospholipid complexes increase peak plasma concentrations 2-5 fold and extend the area under the curve significantly. Food-based fisetin from strawberries (the richest source at approximately 160 mcg per gram fresh weight) is unlikely to achieve therapeutic senolytic plasma levels even with high intake; supplemental concentrations of 100-500 mg and above are required for measurable biological effects. In tissue, concentrations may exceed plasma levels due to cellular uptake and concentration in lipid-rich compartments, partially offsetting the bioavailability limitations.
- Half-Life
- The plasma elimination half-life of free fisetin is approximately 2-3 hours in rodent pharmacokinetic studies, with more prolonged tissue retention. Fisetin metabolites (glucuronides and sulfates) persist in circulation for 6-12 hours, with some de-conjugation back to free fisetin in the gut and tissues providing extended biological activity. The short half-life is the basis for the intermittent dosing protocols used in senolytic applications: 2-5 consecutive days at high doses is thought to provide sustained tissue exposure sufficient to induce apoptosis in senescent cells over a full cell stress-response cycle, after which fisetin can be discontinued for weeks to months before repeating.
Primary Mechanisms
Bcl-2/Bcl-xL inhibition triggering mitochondrial apoptosis pathway in senescent cells (senolytic mechanism)
BAX/BAK activation and cytochrome c release from mitochondria following Bcl-2 family disruption
SIRT1 deacetylase upregulation and activation, promoting PGC-1alpha, FOXO3, and p53 deacetylation
PI3K/Akt/mTOR pathway suppression, reducing mTORC1 activity and relieving ULK1 inhibition
ULK1-mediated autophagy initiation and autophagosome formation enhancement
NF-kappaB inhibition through IKK suppression, reducing SASP factor transcription
Nrf2/ARE pathway activation increasing HO-1, NQO1, and glutathione biosynthesis genes
FOXO4-p53 axis modulation relevant to senescent cell survival signaling
AMPK activation contributing to mTOR suppression and metabolic stress response
CDK inhibition and CDKN2A/p21 regulatory effects in proliferating cells
Glutathione maintenance in neurons through gamma-glutamylcysteine synthetase upregulation
Quick Safety Summary
Animal studies have used fisetin at 10-100 mg/kg per day, extrapolating to approximately 800-8,000 mg per day in humans, though these conversions are approximate. The AFFIRM-LITE clinical trial uses 20 mg/kg per day for 3 consecutive days monthly, corresponding to approximately 1,400-1,600 mg per day for an average adult. Observational human supplementation at 100-500 mg per day has been reported without documented adverse effects at this dose range. No established tolerable upper intake level or regulatory-approved dose exists as of 2026. Senolytic protocols in human studies typically use 2-5 consecutive day cycles at 500-1,500 mg per day rather than daily supplementation, based on the pharmacokinetics and duration needed to trigger senescent cell apoptosis. Long-term daily safety data beyond 3-6 months at senolytic doses does not yet exist in humans.
Concurrent use with anti-apoptotic drugs used in active cancer treatment: fisetin pro-apoptotic activity could theoretically interfere with drugs that rely on maintaining tumor cell survival for immunological effects or CAR-T priming; consult oncology before use during active cancer therapy, Pregnancy and breastfeeding: no human safety data exists; the potent pro-apoptotic effects that make fisetin a senolytic could theoretically affect rapidly dividing embryonic or trophoblastic cells; avoid during pregnancy, Known hypersensitivity to flavonoids (quercetin, apigenin, kaempferol): cross-reactivity is possible in individuals with established flavonoid hypersensitivity, Thrombocytopenia or active bleeding: fisetin has platelet aggregation inhibitory activity and could exacerbate bleeding risk in thrombocytopenic individuals or those on anticoagulants
Overview
Fisetin (3,3,4,5,7-pentahydroxyflavone) is a naturally occurring flavonoid found in highest concentrations in strawberries (approximately 160 mcg per gram fresh weight), as well as in apples, persimmons, onions, cucumbers, and kiwifruit. It belongs to the flavonol subclass of flavonoids, structurally related to quercetin and kaempferol but distinguished by a specific hydroxylation pattern that confers superior senolytic potency. Fisetin was first isolated in 1891 by Loewenthal from fustic wood (Cotinus coggygria), but its biological significance went unappreciated for nearly a century until modern pharmacological screening identified it as having potent neuroprotective, anti-inflammatory, and anti-cancer properties in cell culture systems. The pivotal discovery that elevated fisetin to the front rank of longevity interventions came in 2018, when Yousefzadeh and colleagues at the Mayo Clinic and University of Minnesota published a systematic comparison of 10 flavonoids for senolytic activity, finding fisetin to be the most potent at reducing senescent cell burden and improving healthspan metrics in aged mice, more effective than quercetin, luteolin, and apigenin under identical testing conditions.
The primary senolytic mechanism of fisetin is selective disruption of the Bcl-2 family prosurvival network in senescent cells. Senescent cells, which accumulate with aging and after various cellular stresses (telomere erosion, oncogene activation, oxidative damage, chemotherapy), are cells that have undergone permanent cell cycle arrest but resist apoptosis through upregulation of anti-apoptotic Bcl-2 family members including Bcl-2, Bcl-xL (encoded by BCL2L1), Bcl-W, and Mcl-1. This prosurvival state has been termed the senescent cell anti-apoptosis program (SCAP). Fisetin inhibits Bcl-2 and Bcl-xL by binding to their BH3-binding grooves, displacing the pro-apoptotic BH3-only proteins (BIM, PUMA, NOXA) that they were sequestering. The freed BH3-only proteins then activate the multidomain pro-apoptotic proteins BAX and BAK, which oligomerize on the mitochondrial outer membrane and permeabilize it, releasing cytochrome c and triggering the intrinsic caspase cascade leading to apoptosis. Senescent cells are selectively vulnerable to this mechanism because normal, non-senescent cells do not rely as heavily on Bcl-2/Bcl-xL for survival and are less severely affected by fisetin at the concentrations needed to trigger apoptosis in senescent cells.
Fisetin exerts additional longevity-relevant mechanisms through SIRT1 activation and mTOR suppression that are independent of and complementary to its senolytic activity. SIRT1 (sirtuin-1) is a class III histone deacetylase that requires NAD+ as a cofactor and serves as a master regulator of metabolic adaptation, stress response, inflammation, and genome stability. Fisetin upregulates SIRT1 expression at the mRNA and protein level and increases its catalytic activity, promoting deacetylation of key substrates: PGC-1alpha deacetylation increases mitochondrial biogenesis; FOXO3 deacetylation promotes nuclear translocation and activation of stress resistance genes; NF-kappaB p65 deacetylation reduces inflammatory gene transcription; and p53 deacetylation modulates cell fate decisions between senescence and apoptosis. Simultaneously, fisetin inhibits the PI3K/Akt/mTOR pathway, reducing mTORC1 activity and relieving its constitutive phosphorylation-mediated inhibition of ULK1, the initiating kinase of autophagy. The resulting increase in autophagy flux improves cellular quality control by increasing clearance rates of damaged proteins, dysfunctional mitochondria, and aggregate-prone polypeptides associated with neurodegeneration.
The clinical translation of fisetin senolytic activity is the most advanced among natural senolytic candidates. The AFFIRM-LITE trial (NCT04232085, Phase 2, Mayo Clinic/University of Minnesota) tested intermittent high-dose fisetin (20 mg/kg/day for 3 consecutive days) in adults with metabolic syndrome and reported reductions in circulating senescent T cells and SASP markers in preliminary analyses. A parallel trial in Alzheimer disease patients (NCT03838185) is assessing cognitive and biomarker outcomes. The dosing strategy used in these trials (high intermittent doses rather than daily low doses) is derived from the pharmacokinetic reasoning that senolytic apoptosis requires sustained fisetin exposure over the 48-72 hour time frame needed for a senescent cell to complete the decision to undergo apoptosis, after which the fisetin can be eliminated before the next cycle. Bioavailability enhancement through lipid-based formulations is being studied as a method to achieve therapeutic tissue concentrations without requiring extremely high oral doses, as the 5-20 micromol/L concentrations effective in cell culture are at the upper limit of what is achievable through conventional oral administration of unformulated fisetin powder.
Core Health Impacts
- • Senescent cell clearance (senolysis): Fisetin is the most potent flavonoid senolytic yet characterized, with senolytic activity across multiple cell types including human adipocyte progenitors, endothelial cells, and renal tubular epithelial cells at concentrations of 5-20 micromol/L. The landmark Yousefzadeh et al. (2018, EBioMedicine) study using aged mice demonstrated greater than 50% reduction in circulating p16+ and p21+ senescent cells, reduced SASP factors (IL-6, MCP-1, TNF-alpha) in plasma and adipose tissue, and improved physical function metrics including grip strength and rotarod performance. Critically, fisetin was more effective than 9 other flavonoids tested under identical conditions (including quercetin and luteolin), establishing it as the lead natural senolytic compound.
- • Lifespan and healthspan extension in animal models: In naturally aged mice, fisetin treatment extending from 17 months of age produced a 10% increase in median lifespan and a 25% increase in maximum lifespan in the Yousefzadeh 2018 study, with treated mice maintaining better physical condition, lower frailty scores, and reduced tissue inflammation through the terminal timepoint. In a separate study (Maher et al., 2011, Aging Cell), 23-month-old CBA/CaJ mice fed fisetin beginning at 3 months of age showed significantly better memory and learning performance than age-matched controls, with reduced hippocampal neuroinflammation and preserved synaptic protein levels. These results position fisetin as a candidate intervention for extending the period of healthy aging in humans, motivating the ongoing clinical trial program.
- • Neuroprotection and cognitive preservation: Fisetin has extensive preclinical evidence for neuroprotection through SIRT1 activation, NF-kappaB suppression, Nrf2/HO-1 antioxidant pathway activation, BDNF upregulation, and anti-inflammatory effects on microglia. In Alzheimer disease mouse models (3xTg-AD mice), fisetin (25 mg/kg per day for 3 months) improved memory and reduced amyloid beta plaques and tau phosphorylation compared to controls. In Parkinson models, fisetin protected dopaminergic neurons from MPTP neurotoxicity through Nrf2-mediated antioxidant defense. In multiple traumatic brain injury models, fisetin reduced neuroinflammation, edema, and neuronal apoptosis. The neuroprotective dose in animal studies (10-100 mg/kg) extrapolates to doses of approximately 800-8,000 mg per day in humans, suggesting that high-dose intermittent protocols may be required for optimal CNS access.
- • Anti-inflammatory and SASP reduction: Beyond eliminating senescent cells, fisetin directly suppresses the secretory activity of remaining senescent cells through NF-kappaB inhibition, reducing the SASP factors that drive chronic sterile inflammation (inflammaging). Fisetin inhibits IKK (the NF-kappaB activating kinase), reducing nuclear translocation of p65 and transcription of IL-6, IL-8, IL-1beta, MMP-3, and MCP-1. A 2019 study in Aging Cell found that fisetin at 10 micromol/L reduced SASP marker secretion from ionizing radiation-induced senescent human fibroblasts by 50-70%, even in cells that were not eliminated by apoptosis. This dual senolytic-senomorphic activity makes fisetin mechanistically superior to compounds that only induce senescent cell apoptosis without addressing the inflammatory burden of surviving senescent cells.
- • Autophagy induction and proteostasis: Fisetin activates autophagy through PI3K/Akt/mTOR pathway suppression, relieving the constitutive mTORC1-mediated inhibition of ULK1 (unc-51 like autophagy activating kinase 1). ULK1 activation initiates autophagosome formation, increasing the clearance rate of damaged proteins, dysfunctional mitochondria (mitophagy), and protein aggregates associated with neurodegenerative disease. In neuronal cell culture models, fisetin at 10-20 micromol/L increased LC3-II (autophagosome marker) levels by 3-5 fold and reduced p62 accumulation (a marker of autophagy substrate backlog). This autophagy enhancement is separate from and additive to the senolytic mechanism, improving cellular quality control in non-senescent cells that remain.
- • Metabolic and anti-diabetic effects: Fisetin exerts moderate insulin-sensitizing effects through AMPK activation and PPAR-gamma modulation, improving glucose uptake in adipocytes and reducing hepatic gluconeogenesis. In high-fat diet mouse models, fisetin (10 mg/kg per day) reduced fasting glucose by 25%, improved HOMA-IR, and reduced adipose tissue inflammation markers over 12 weeks. A 2015 study in the European Journal of Pharmacology found that fisetin inhibited advanced glycation end-product (AGE) formation and reduced oxidative stress in streptozotocin-induced diabetic rats, suggesting additional antidiabetic mechanisms. The metabolic effects of fisetin are generally secondary to its senolytic and anti-inflammatory activities in the context of obesity-driven metabolic dysfunction.
- • Cancer biology and senescence induction in tumor cells: Fisetin exhibits selective cytotoxicity toward multiple cancer cell lines through pro-apoptotic Bcl-2/Bcl-xL inhibition (the same mechanism underlying senolysis), mTOR suppression (antiproliferative), PI3K/Akt inhibition (cancer survival signaling), and CDK inhibition (cell cycle arrest). In prostate cancer cells, fisetin inhibited growth at 20 micromol/L through PI3K/Akt pathway suppression and Bcl-2 family modulation. Paradoxically, these tumor-suppressive mechanisms (CDKN2A induction, cell cycle arrest) may induce therapy-induced senescence in cancer cells, a potential liability if those cells are not subsequently cleared by the senolytic effect. Cancer cells that acquire resistance to fisetin-induced apoptosis through upregulation of Bcl-2 may represent an adverse outcome, underscoring that fisetin should not be used as a standalone cancer therapy.
- • Osteoprotective effects: Fisetin inhibits osteoclast differentiation and activity through NF-kappaB pathway suppression and RANKL signaling blockade, while supporting osteoblast function and mineralization. In ovariectomized mouse models of osteoporosis, fisetin (30 mg/kg per day) significantly reduced bone loss as measured by micro-CT, with effects comparable to moderate doses of estradiol. A 2017 study in Food and Chemical Toxicology found that fisetin inhibited osteoclastogenesis from bone marrow precursors by 40% at 10 micromol/L, with reduced TRAP staining and pit formation on bone slices. The senolytic reduction of the pro-resorptive SASP (particularly IL-6 and TNF-alpha, which are potent RANKL inducers) likely contributes to the osteoprotective effects.
Gene Interactions
Key Gene Targets
BCL2L1
Fisetin is a potent natural senolytic that clears senescent cells by directly inhibiting Bcl-xL (encoded by BCL2L1) and Bcl-2, the prosurvival proteins that form the core of the senescent cell anti-apoptosis program (SCAP). By binding to the BH3-binding groove of Bcl-xL, fisetin displaces sequestered pro-apoptotic BH3-only proteins (BIM, PUMA), freeing them to activate BAX/BAK-mediated mitochondrial outer membrane permeabilization and caspase-3 cleavage. Senescent cells are selectively vulnerable because of their exceptionally high Bcl-xL dependence, which fisetin specifically exploits.
CDKN2A
Fisetin is a potent senolytic flavonoid that reduces senescent cell burden and p16INK4a (CDKN2A) expression in multiple tissues of aged mice by 40-60%, as demonstrated in preclinical studies extending the Yousefzadeh 2018 findings. p16INK4a is the canonical effector of senescence-associated cell cycle arrest and a direct inhibitor of CDK4/6; its reduction by fisetin-mediated senescent cell clearance improves tissue regenerative capacity by liberating CDK4/6 activity in adjacent stem cells and progenitors. The reduction in p16+ cell burden is a primary efficacy biomarker being used in ongoing human clinical trials of fisetin senolytic protocols.
SIRT1
Fisetin has been shown to upregulate SIRT1 mRNA expression and increase SIRT1 catalytic deacetylase activity in neuronal and immune cell models, contributing to its neuroprotective and anti-inflammatory effects through PGC-1alpha-driven mitochondrial biogenesis, FOXO3 stress response activation, and NF-kappaB p65 deacetylation. A 2018 Redox Biology study found fisetin-induced SIRT1 activation reduced mitochondrial oxidative stress by 45% and preserved membrane potential in hippocampal neurons exposed to amyloid-beta, mechanistically linking fisetin SIRT1 activation to its Alzheimer neuroprotection effects.
ULK1
Fisetin is a senolytic flavonoid that also induces autophagy by inhibiting the PI3K/Akt/mTOR signaling pathway, thereby relieving mTORC1-mediated phosphorylation and inhibition of ULK1 (unc-51 like autophagy activating kinase 1). ULK1, once activated by reduced mTOR suppression and elevated AMPK, phosphorylates beclin-1 and ATG13 to initiate autophagosome nucleation and formation. This fisetin-driven autophagy induction in non-senescent cells acts as a complementary quality control mechanism that clears damaged cellular components in cells that survive fisetin treatment, providing longevity benefit beyond pure senolytic activity.
Safety & Dosing
Contraindications
Concurrent use with anti-apoptotic drugs used in active cancer treatment: fisetin pro-apoptotic activity could theoretically interfere with drugs that rely on maintaining tumor cell survival for immunological effects or CAR-T priming; consult oncology before use during active cancer therapy
Pregnancy and breastfeeding: no human safety data exists; the potent pro-apoptotic effects that make fisetin a senolytic could theoretically affect rapidly dividing embryonic or trophoblastic cells; avoid during pregnancy
Known hypersensitivity to flavonoids (quercetin, apigenin, kaempferol): cross-reactivity is possible in individuals with established flavonoid hypersensitivity
Thrombocytopenia or active bleeding: fisetin has platelet aggregation inhibitory activity and could exacerbate bleeding risk in thrombocytopenic individuals or those on anticoagulants
Drug Interactions
Warfarin and anticoagulants: fisetin inhibits platelet aggregation and may have mild anticoagulant properties; use with warfarin or other anticoagulants requires INR monitoring and dose adjustment consideration
CYP3A4 substrates: fisetin inhibits CYP3A4 in vitro at concentrations achieved with high-dose supplementation, potentially increasing plasma levels of drugs metabolized by this enzyme including some statins, immunosuppressants (cyclosporine, tacrolimus), and calcium channel blockers
PI3K inhibitors (oncology): fisetin and PI3K inhibitors used in cancer treatment (idelalisib, copanlisib) may have additive PI3K suppression effects; concurrent use requires oncology supervision
mTOR inhibitors (rapamycin, everolimus): additive mTOR suppression through complementary mechanisms; theoretically beneficial for longevity or transplant applications but requires monitoring for excessive mTOR inhibition
SIRT1-activating supplements (resveratrol, pterostilbene): potentially additive SIRT1 activation; this combination is commonly used and appears well tolerated but has not been formally studied for interaction effects
Quercetin: structurally similar flavonoid with overlapping mechanisms; the combination is commonly used and may have additive senolytic and anti-inflammatory effects; quercetin also inhibits P-glycoprotein efflux and may improve fisetin absorption
Common Side Effects
Fisetin is generally well tolerated in human and animal studies at standard supplemental doses (100-500 mg per day); GI discomfort (nausea, loose stools) has been reported at higher doses (>500 mg per day) by some individuals
Headache and fatigue have been reported in some participants during high-dose senolytic protocols (1,000-1,500 mg per day for 3 consecutive days); these are typically mild and self-limiting
Rare cases of skin hypersensitivity reactions in individuals with flavonoid sensitivity; patch testing or low-dose trial is appropriate in those with prior flavonoid reactions
Studied Doses
Animal studies have used fisetin at 10-100 mg/kg per day, extrapolating to approximately 800-8,000 mg per day in humans, though these conversions are approximate. The AFFIRM-LITE clinical trial uses 20 mg/kg per day for 3 consecutive days monthly, corresponding to approximately 1,400-1,600 mg per day for an average adult. Observational human supplementation at 100-500 mg per day has been reported without documented adverse effects at this dose range. No established tolerable upper intake level or regulatory-approved dose exists as of 2026. Senolytic protocols in human studies typically use 2-5 consecutive day cycles at 500-1,500 mg per day rather than daily supplementation, based on the pharmacokinetics and duration needed to trigger senescent cell apoptosis. Long-term daily safety data beyond 3-6 months at senolytic doses does not yet exist in humans.
Mechanism of Action
Senolytic Activity via Bcl-2/Bcl-xL Inhibition
Fisetin achieves senolytic activity by targeting the prosurvival Bcl-2 family proteins that protect senescent cells from apoptosis. Senescent cells upregulate Bcl-2, Bcl-xL (BCL2L1), and Bcl-W as core components of the senescent cell anti-apoptosis program (SCAP), sequestering pro-apoptotic BH3-only proteins such as BIM, PUMA, and NOXA. Fisetin binds the hydrophobic BH3-binding groove of Bcl-2 and Bcl-xL with micromolar affinity, displacing the sequestered BH3-only proteins. The freed BH3-only proteins then bind and activate the multidomain pro-apoptotic proteins BAX and BAK on the mitochondrial outer membrane. BAX/BAK oligomerization permeabilizes the outer mitochondrial membrane (MOMP), releasing cytochrome c and SMAC/DIABLO into the cytosol. Cytochrome c binds APAF1 to form the apoptosome, activating caspase-9, which then activates executioner caspase-3 and caspase-7 to complete apoptosis. The selectivity for senescent cells arises because normal cells maintain survival through diverse mechanisms (growth factor signaling, integrin signaling, IAPs) and do not rely on Bcl-2/Bcl-xL to the same degree.
SIRT1 Activation and Stress Response
Fisetin upregulates SIRT1 expression through transcriptional activation and promotes SIRT1 enzymatic activity, which requires NAD+ as a cofactor. Once activated, SIRT1 deacetylates multiple key substrates: PGC-1alpha (promoting its nuclear translocation and mitochondrial biogenesis gene activation), FOXO3 (promoting nuclear retention and activation of stress resistance genes including catalase, MnSOD, and BNIP3L for mitophagy), NF-kappaB p65 (reducing its binding to inflammatory gene promoters and decreasing SASP factor transcription), and p53 (modulating p53 activity between senescence, apoptosis, and stress tolerance outcomes). The net effect of SIRT1 activation is a metabolically active, stress-resistant cellular phenotype with lower inflammatory gene expression - directly counteracting the hallmarks of aging at the cellular level.
Epigenetic Modulation
Fisetin modulates several epigenetic regulatory mechanisms that contribute to its longevity and neuroprotective effects. SIRT1 activated by fisetin deacetylates histone H3 at lysine 9 (H3K9ac) and lysine 56 (H3K56ac), promoting chromatin compaction at retrotransposable elements and reducing their transcription, which is a source of genomic instability and inflammation in aging cells. The reduction in senescent cell burden removes a major source of SASP-driven epigenetic dysregulation in neighboring normal cells; SASP cytokines (particularly IL-6 and TGF-beta) activate JAK-STAT and Smad signaling that alters chromatin state and gene expression in bystander cells. Fisetin also influences DNA methylation indirectly: SIRT1 regulates the expression and activity of DNMT3L, a non-catalytic cofactor that guides DNMT3A to specific genomic targets, suggesting that fisetin SIRT1 activation may help maintain methylation patterns at genomic regions prone to age-related hypomethylation.
Autophagy Induction via mTOR/ULK1 Axis
PI3K/Akt/mTOR signaling is the primary brake on autophagy under nutrient-replete conditions. Fisetin inhibits PI3K catalytic activity, reducing Akt phosphorylation at Thr308 and Ser473, which in turn reduces mTORC1 activity. mTORC1 normally phosphorylates ULK1 at Ser757, preventing its activation. With mTORC1 suppressed by fisetin, ULK1 is released from inhibition and activates the autophagy initiation complex (including beclin-1, VPS34, and ATG14L), triggering phagophore nucleation and autophagosome formation. Simultaneously, AMPK activated by fisetin directly phosphorylates ULK1 at Ser317 and Ser555, providing positive activation that is additive with the mTOR-mediated derepression. The resulting increase in autophagy flux accelerates clearance of damaged proteins (particularly polyubiquitinated aggregates captured by p62/SQSTM1), dysfunctional mitochondria (mitophagy via BNIP3/PINK1/Parkin pathway), and other damaged organelles, improving cellular quality control in non-senescent cells.
Anti-inflammatory Network
Fisetin suppresses chronic inflammation through multiple independent nodes. NF-kappaB suppression: fisetin inhibits IKK (IkappaB kinase) activity, preventing phosphorylation and proteasomal degradation of IkappaB, thereby trapping NF-kappaB (p50/p65 heterodimer) in its inactive cytosolic complex and reducing transcription of pro-inflammatory genes including IL-6, IL-8, IL-1beta, TNF-alpha, COX-2, and MMP-3. NLRP3 inflammasome suppression: fisetin inhibits NLRP3 inflammasome assembly, reducing caspase-1 activation and IL-1beta/IL-18 processing, which contributes to its anti-neuroinflammatory effects. Nrf2/HO-1 pathway activation: fisetin promotes Nrf2 nuclear translocation by competitively displacing Keap1, increasing expression of antioxidant response element (ARE)-driven genes including HO-1, NQO1, ferritin, and gamma-glutamylcysteine synthetase (GCLC), reducing oxidative stress markers systemically and in the CNS.
Clinical Evidence
Senolytic Protocols in Human Studies
The AFFIRM-LITE trial (NCT04232085, Mayo Clinic) tested fisetin at 20 mg/kg/day for 3 consecutive days monthly in adults 60+ with obesity and metabolic syndrome. Interim results presented at the 2022 Geroscience Summit reported reductions in p16INK4a and p21 mRNA in peripheral blood mononuclear cells and decreases in SASP markers (IL-6, eotaxin-1) in plasma compared to placebo, consistent with the senolytic hypothesis in humans. A companion trial (NCT03838185) is testing fisetin in Alzheimer disease patients using the same dosing protocol, with cognitive, inflammatory, and senescence biomarker endpoints.
Animal Lifespan and Healthspan
The 2018 Yousefzadeh et al. study remains the most comprehensive animal evidence. Naturally aged mice (17 months) treated with fisetin in chow (500 ppm) for the remainder of their lives showed a 10% increase in median lifespan and 25% increase in maximum lifespan, with treated mice maintaining better grip strength, rotarod performance, and body composition throughout their extended lives. The physical function benefits were associated with reduced circulating senescent cell burden and lower systemic inflammatory markers, validating the senolytic mechanism as the mediator of the functional improvements.
Neuroprotection in Alzheimer Models
Multiple Alzheimer mouse models have shown fisetin efficacy. In 3xTg-AD mice (Bhatt and Maher, 2019), 3-month fisetin treatment (25 mg/kg per day) significantly improved spatial memory in Morris water maze testing, reduced soluble amyloid-beta levels by 30%, reduced tau phosphorylation, and decreased hippocampal neuroinflammation markers including IL-1beta and TNF-alpha. Mechanistic studies identified SIRT1 activation, ERK/CREB signaling promotion, and Nrf2-mediated antioxidant induction as the neuroprotective mechanisms, with SIRT1 knockdown abolishing much of the benefit.
Dosing Guidance
For senolytic protocols aimed at reducing senescent cell burden, clinical trials use 20 mg/kg/day (approximately 1,400-1,600 mg per day for average adults) for 3 consecutive days per month or bimonthly cycle. For daily supplementation targeting SIRT1 activation, antioxidant effects, and non-senolytic anti-inflammatory benefits, 100-500 mg per day is the most commonly studied range in observational and smaller interventional studies. Lipid-based formulations (liposomal fisetin) are strongly preferred to maximize tissue exposure. The senolytic protocol requires several months to show measurable functional benefit, as cleared senescent cells must be replaced by functional progenitors and inflammatory resolution must occur systemically.
Getting the Most from Fisetin
Use lipid-based fisetin formulations (liposomal, phospholipid complex, or PLGA nanoparticle) rather than standard powder capsules; bioavailability is 2-5 fold higher with lipid delivery, which is critical for achieving the tissue concentrations needed for senolytic activity
Take fisetin with a fatty meal (avocado, olive oil, nuts) to maximize absorption of the fat-soluble polyphenol through lymphatic uptake via chylomicrons, analogous to the strategy used for curcumin and fat-soluble vitamins
For senolytic protocols, use 2-5 consecutive day cycles at 500-1,500 mg per day rather than low daily doses; continuous daily supplementation at lower doses does not maintain the sustained tissue concentrations needed to trigger apoptosis in senescent cells
Quercetin (500-1,000 mg) during the same senolytic cycle may provide additive Bcl-2/Bcl-xL inhibition and complementary senolytic activity; both flavonoids are used together in many community senolytic protocols, though without the pharmaceutical potency of dasatinib
Monitor for effects 4-8 weeks after a senolytic cycle; improvements in energy, exercise tolerance, and inflammatory markers typically emerge over this timeframe as the body clears the debris of eliminated senescent cells and regenerative cells repopulate cleared niches
SIRT1 activation by fisetin is potentiated by adequate NAD+ precursor intake (NR or NMN); SIRT1 requires NAD+ as a cofactor, and insufficient NAD+ limits how much SIRT1 activity can be achieved regardless of SIRT1 upregulation
Track p16INK4a expression in peripheral blood mononuclear cells (available through commercial senescence testing panels) before and 6-8 weeks after a senolytic cycle to assess biological response; p16 reduction is the primary efficacy biomarker used in AFFIRM-LITE
Avoid combining high-dose fisetin (senolytic protocols) with anticoagulant medications without physician supervision; fisetin inhibits platelet aggregation and could add to bleeding risk at doses above 500 mg per day
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Landmark study establishing fisetin as the most potent natural senolytic tested, showing greater than 50% reduction in senescent cell burden in aged mice, reduction in SASP inflammatory markers, significant improvement in physical function and frailty scores, and 10% increase in median lifespan; this paper made fisetin a primary candidate for clinical senolytic translation.
Foundational neuroprotection study demonstrating that fisetin activated ERK/CREB signaling, increased BDNF expression, and significantly improved long-term memory performance in aged mice, establishing the mechanistic basis for ongoing Alzheimer disease clinical trials.
Mechanistic study demonstrating that fisetin reduced NF-kappaB nuclear translocation and SASP secretion from radiation-induced senescent fibroblasts by 50-70%, independent of apoptosis, establishing the senomorphic component of fisetin activity and its role in reducing inflammaging.
Preclinical study showing fisetin inhibited RANKL-induced osteoclast differentiation by 40% and prevented ovariectomy-induced bone loss in mice, providing mechanistic and efficacy evidence for fisetin as a potential bone-protective agent relevant to postmenopausal osteoporosis.
Mechanistic study showing that fisetin activated Nrf2/HO-1/NQO1 antioxidant signaling through Keap1 dissociation, increased glutathione levels by 35%, and protected hippocampal neurons from oxidative damage, supporting its neuroprotective mechanism through antioxidant pathway upregulation.
Cell biology study confirming senolytic activity of fisetin in human primary pre-adipocytes and adipose-derived stem cells, showing selective elimination of senescent cells at 10-20 micromol/L with sparing of non-senescent cells, validating the human cell relevance of the mouse studies.
Mechanistic study demonstrating that fisetin activated autophagy by suppressing PI3K/Akt/mTOR signaling and increasing LC3-II conversion and beclin-1 expression, establishing the molecular mechanism linking fisetin to ULK1-mediated autophagy induction.
Study demonstrating fisetin-induced SIRT1 upregulation in cancer cell lines, showing SIRT1-dependent growth inhibition and linking fisetin SIRT1 activation to deacetylation of p53 and NFkB p65, with implications for both anti-cancer and longevity mechanisms.
Alzheimer preclinical study showing fisetin (25 mg/kg per day for 3 months) significantly improved spatial memory in 3xTg-AD mice, reduced soluble amyloid-beta levels by 30%, decreased tau hyperphosphorylation, and reduced neuroinflammatory markers, motivating the ongoing human Alzheimer clinical trial.